133 related articles for article (PubMed ID: 36178197)
1. A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD; Lock JP; Frias JP; Tinahones FJ; Dahl D; Conery AL; Freeman MW
Diabetes Obes Metab; 2023 Jan; 25(1):293-301. PubMed ID: 36178197
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
Xie L; Han J; Cheng Z; Liu D; Liu J; Xu C; Sun W; Li Q; Bian F; Zhang W; Chen J; Zhu Q; Thurber TK; Lock JP; Zhang B
J Diabetes; 2024 Apr; 16(4):e13526. PubMed ID: 38584148
[TBL] [Abstract][Full Text] [Related]
3. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
Halvorsen YD; Conery AL; Lock JP; Zhou W; Freeman MW
Diabetes Obes Metab; 2023 Oct; 25(10):2954-2962. PubMed ID: 37409573
[TBL] [Abstract][Full Text] [Related]
4. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD; Lock JP; Zhou W; Zhu F; Freeman MW
Diabetes Obes Metab; 2019 Oct; 21(10):2248-2256. PubMed ID: 31161692
[TBL] [Abstract][Full Text] [Related]
5. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
Schernthaner G; Rosas-Guzmán J; Dotta F; Guerci B; Simó R; Festa A; Kiljański J; Zhou M; Gallwitz B
Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
[TBL] [Abstract][Full Text] [Related]
6. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.
Halvorsen YD; Walford G; Thurber T; Russell H; Massaro M; Freeman MW
Diabetes Obes Metab; 2020 Apr; 22(4):566-573. PubMed ID: 31749238
[TBL] [Abstract][Full Text] [Related]
8. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Halvorsen YC; Walford GA; Massaro J; Aftring RP; Freeman MW
Diabetes Obes Metab; 2019 Nov; 21(11):2496-2504. PubMed ID: 31297965
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
[TBL] [Abstract][Full Text] [Related]
10. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Cefalu WT; Leiter LA; Yoon KH; Arias P; Niskanen L; Xie J; Balis DA; Canovatchel W; Meininger G
Lancet; 2013 Sep; 382(9896):941-50. PubMed ID: 23850055
[TBL] [Abstract][Full Text] [Related]
12. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
13. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
[TBL] [Abstract][Full Text] [Related]
19. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
Gu T; Ma J; Zhang Q; Zhu L; Zhang H; Xu L; Cheng J; Shi B; Li D; Shao J; Sun Z; Zhong S; Bi Y; Zhu D
Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Gallo S; Charbonnel B; Goldman A; Shi H; Huyck S; Darekar A; Lauring B; Terra SG
Diabetes Obes Metab; 2019 Apr; 21(4):1027-1036. PubMed ID: 30614616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
